Salkeni, M. A., Sommerhalder, D., Vandross, A. L., Puri, K. D., Bouchlaka, M. N., Sarapa, N., Skingley, L., Yefimenko, M., Bexon, A. S., Cronier, D., Sen, S. (2025). Phase 2 expansions of OR502, an antibody targeting leukocyte immunoglobulin-like receptor B2 (LILRB2) ± cemiplimab in patients with advanced solid tumors.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps2669